Efficacy of immunotherapy in lung cancer with co-occurring mutations in NOTCH and homologous repair genes

BACKGROUND: Immune checkpoint inhibitors (ICIs) provide significant survival benefits in non-small cell lung cancer (NSCLC). Nevertheless, while some patients obtain a prolonged benefit, a non-negligible fraction of patients experiences an ultrarapid disease progression. Identifying specific molecul...

Descripción completa

Detalles Bibliográficos
Autores principales: Mazzotta, Marco, Filetti, Marco, Occhipinti, Mario, Marinelli, Daniele, Scalera, Stefano, Terrenato, Irene, Sperati, Francesca, Pallocca, Matteo, Rizzo, Francesco, Gelibter, Alain, Botticelli, Andrea, Scafetta, Giorgia, Di Napoli, Arianna, Krasniqi, Eriseld, Pizzuti, Laura, Barba, Maddalena, Carpano, Silvia, Vici, Patrizia, Fanciulli, Maurizio, De Nicola, Francesca, Ciuffreda, Ludovica, Goeman, Frauke, De Maria, Ruggero, Vecchione, Andrea, Giusti, Raffaele, Ciliberto, Gennaro, Marchetti, Paolo, Maugeri-Saccà, Marcello
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7409965/
https://www.ncbi.nlm.nih.gov/pubmed/32759236
http://dx.doi.org/10.1136/jitc-2020-000946

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7409965/
https://www.ncbi.nlm.nih.gov/pubmed/32759236
http://dx.doi.org/10.1136/jitc-2020-000946

Ejemplares similares